p53 Protein overexpression in gallbladder carcinoma and its precursor lesions: An immunohistochemical study

Human Pathology

Volumn 27, Issue 4, 1996, Pages 360-365

  Wistuba, Ignacio I ^b   Gazdar, Adi F ^b   Roa, Ivan ^b   Albores Saavedra, Jorge ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b NONE

Author keywords

gallbladder carcinoma; immunohistochemistry; p53; premalignant lesions

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER INFILTRATION; CANCER INVASION; CARCINOMA IN SITU; CLINICAL ARTICLE; DYSPLASIA; GALLBLADDER CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PROTEIN ANALYSIS;

EID: 0029864322     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(96)90109-4     Document Type: Article

References (40)

1. Albores-Saavedra J, Henson DE: Etiologic considerations, in Hartman WH (ed): Tumors of the Gallbladder and Extrahepatic Bile Ducts: Atlas of Tumor Pathology (second series, fascicle 22). Washington, DC: Armed Forces Institute of Pathology, 1986, pp 38-43
2. Serra I, Calvo A, Csendes A, et al: Gastric and gallbladder carcinoma in Chile: Epidemiological changes and control programs. Rev Med Chil 117:834-836, 1989 (letter)
3. Abi-Rached B, Neugut A: Diagnostic and managment issues in gallbladder carcinoma. Oncology 9:19-30, 1995
4. Albores-Saavedra J, Alcantra-Vazquez A, Cruz-Ortiz H, et al: The precursor lesions of invasive gallbladder carcinoma: Hyperplasia, atypical hyperplasia and carcinoma in situ. Cancer 45:919-927, 1980
5. Albores-Saavedra J, Manrique JJ, Angeles-Angeles A, et al: Carcinoma in situ of the gallbladder: A clinicopathologic study of 18 cases. Am J Surg Pathol 8:323-333, 1984
6. Vogelstein B, Kinzler K: p53 Function and dysfunction. Cell 70:523-526, 1992
7. Greenblatt MS, Bennett WP, Hollstein M, et al: Mutations in the p53 tumor supressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994
8. Hollstein M, Sidransky D, Vogelstein B, et al: p53 Mutations in human cancers. Science 253:49-53, 1991
9. Bartek J, Bartkova J, Vojtesek B, et al: Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699-1703, 1991
10. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708, 1989
11. Wagata T, Shibagaki I, Imamura M, et al: Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 53:846-850, 1993
12. Cunningham J, Lust JA, Schaid DJ, et al: Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 52:1974-1980, 1992
13. Gao H, Wang LD, Zhou Q, et al: p53 Tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 54:4342-4346, 1994
14. Sheu L-F, Chen A, Tseng H-H, et al: Assessment of p53 expression in nasopharyngeal carcinoma. HUM PATHOL 26:375-379, 1995
15. Kamel D, Paakko P, Nuorva K, et al: p53 And c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder. J Pathol 170:67-72, 1993
16. Wee A, Teh M, Raju GC: Clinical importance of p53 protein in gallbladder carcinoma and its precursor lesions. J Clin Pathol 47:453-456, 1994
17. Teh M, Wee A, Raju GC: An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer 74:1542-1545, 1994
18. Albores-Saavedra J, Henson DE, Sobin LH: Histological typing of tumours of the gallbladder and extrahepatic bile ducts, in World Health Organization International Histological Classification of Tumours (ed 2). Berlin, Springer-Verlag, 1991, pp 7-21
19. Battifora H: p53 Immunohistochemistry: A word of caution. HUM PATHOL 25:435-437, 1994 (editorial)
20. Wistuba II, Sugio K, Hung J, et al: Allele specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res 55:2511-2515, 1995
21. Kennedy SM, Macgeogh C, Jaffe R, et al: Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with mutations. HUM PATHOL 25:438-442, 1994
22. Cesarman E, Inghirami G, Chadburn A, et al: High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 143:845-856, 1993
23. Matsushima AY, Cesarman E, Chadburn A, et al: Postthymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol 144:573-584, 1994
24. Cordon-Cardo C, Dalbagni G, Saez GT, et al: p53 Mutations in human bladder cancer: Genotypic versus phenotypic patterns. Int J Cancer 56:347-353, 1994
25. Esrig D, Spruck CHd, Nichols PW, et al: p53 Nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397, 1993
26. Scarpa A, Capelli P, Mukai K, et al: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 142:1534-1543, 1993
27. Baas IO, Mulder J-W, Offerhaus JA, et al: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5-12, 1994
28. Bodner SM, Minna JD, Jensen SM, et al: Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749, 1992
29. Hall P, Lane D: p53 In tumor pathology: Can we trust immunohistochemistry? Revisted! J Pathol 172:1-4, 1994
30. McKee PH, Hobbs C, Hall PA: Antigen retrieval by microwave irradiation lowers immunohistological detection thresholds. Histopathology 23:377-379, 1993
31. Hamelin R, Flejou JF, Muzeau F, et al: TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 107:1012-1018, 1994
32. ZhengJ, Shu Q, Li ZH, et al: Patterns of p53 mutations in squamous cell carcinoma of the lung: Acquisition at a relatively early age. Am J Pathol 145:1444-1449, 1994
33. Walker C, Robertson LJ, Myskow MW, et al: p53 Expression in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer 70:297-303, 1994
34. Fukunaga M, Monden T, Nakanishi H, et al: Immunohistochemical study of p53 in gastric carcinoma. Am J Clin Pathol 101:177-180, 1994
35. Baker SJ, Preisinger AC, Jessup JM, et al: p53 Gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717-7722, 1990
36. Lassam NJ, From L, Kahn HJ: Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 53:2235-2238, 1993
37. Baytner S, Mitmaker B, Gordon PH, et al: Immunohistochemical expression of mutant p53 oncogene in transitional mucosa adjacent to human colon cancer. Clin Invest Med 16:379-385, 1993
38. Magee JW, McCalmont TH, LeBoit PE: Overexpression of p53 tumor suppressor protein in porokeratosis. Arch Dermatol 130:187-190, 1994
39. Wood MW, Medina JE, Thompson GC, et al: Accumulation of the p53 tumor-suppressor gene product in oral leukoplakia. Otolaryngol Head Neck Surg 111:758-763, 1994
40. Imai M, Hoshi T, Ogawa K: K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis. Cancer 73:27-33, 1994